Reparixin

Next Previous
Drug Profile

Reparixin

Alternative Names: DF-1681Y; Repertaxin; Repertaxin L-Lysine salt

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dompe Farmaceutici
  • Developer Dompe Farmaceutici; Fox Chase Cancer Center; SatRx; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Benzeneacetamides; Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Delayed graft function
  • Phase II Breast cancer; Liver transplant rejection
  • Discontinued Cerebral ischaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
  • 28 Oct 2016 Phase-II clinical trials in Delayed graft function (Prevention) in Russia (IV) before October 2016 (Dompé pipeline, October 2016)
  • 28 Oct 2016 Dompé Farmaceutici and SatRx plan a phase II/III trial for Delayed graft function in liver transplant patients in Russia (Dompé website, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top